Background: The majority of individuals with type 2 diabetes [T2DM] are aware that in order to prevent microvascular diseases, they must maintain a healthy glycemic control. Since type 2 diabetes progresses with time, insulin therapy will eventually be required and beneficial for many patients, even though initial control can be obtained with lifestyle changes and oral antihyperglycemic medications. Insulin therapy, however, is linked to a higher frequency of hypoglycemia, which exposes patients to a variety of autonomic and neuroglycopenic symptoms.
The aim of the work: The aim of our study is to evaluate the effectiveness and safety of Insulin Glargine 100U and 300U in South Indian Type 2 Diabetes population.
Patients and Methods: Outpatients with adult type 2 diabetes who receive Glargine 100 U [Gla-100] as their basal insulin and outpatients with type 2 diabetes receiving Gla-300 treatment were included in the study population. For a span of two visits, the patients' diabetic therapy remained unchanged, with the exception of the Gla 100 dosage, before they were converted from Gla-100 to Gla-300 between July 2021 and June 2022. Retrospective enrolment in the current trial was made for patients who used Gla-100 continuously during the observational period without changing their other prescription regimen.
Results: The HbA1c levels were significantly decreased after switching [p<0.022]. The patients who remained taking Gla-100 at the same time period showed no change in their HbA1c levels. The patients' BMI values decreased significantly [p<0.023] and the patients who continued using Gla-100 showed no change in their BMI readings. Throughout the follow-up period, the rates of adverse events and hypoglycemia were unchanged.
Conclusion: Gla-100 to Gla-300 at the same dosage should be safe for people with Type 2 diabetes. This switch should aid in controlling body weight and blood sugar levels and is suitable for use in an outpatient setting.